-- Once-a-day tablet Daxas(R) (roflumilast) is a first-in-class treatment under development targeting inflammation, the underlying cause of chronic obstructive pulmonary disease (COPD) ZURICH...
NEW YORK, Aug. 10 /PRNewswire-FirstCall/ -- -- Forest Laboratories acquires exclusive commercialisation rights to Daxas in the United States in treatment of symptomatic COPD -- Nycomed...
DALLAS, June 22 /PRNewswire/ -- BeaconEquity.com announces the availability of stock alerts on today's active stocks. Stock alerts highlight recent news, trading activity and relevant market...
Data Presented at the 2008 International Conference of the American Thoracic Society TORONTO, May 20 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and Laboratorios Almirall, S.A. today...
NEW YORK, Nov. 8 /PRNewswire/ -- Total daily dosages of milnacipran 100 mg and 200 mg demonstrated statistically significant and clinically meaningful improvements in both pain and other core...
NEW YORK, May 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that its licensing partner Mylan Laboratories (NYSE:MYL) submitted a response to the approvable...
In the news release, "Forest Laboratories Revises Research and Development Spending Projection to Account for Upfront Payments for Two Recent In-Licensing Transactions" issued today, Feb. 15, by...
RNS Number:3979H Firth Rixson PLC 12 February 2003 Firth Rixson plc ("the Company") Firth Rixson plc was advised on 11 February 2003 that Deutsche Bank AG and its subsidiary companies no...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관